Physician profile
Andrew Block
NPI 1912931643
$2,078.58
in general payments reported to CMS, 2019-2025
28 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $334 · 2021: $568 · 2022: $120 · 2023: $355 · 2024: $231 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.58 | 2019-2025 | Lo Loestrin Fe |
| Astellas Pharma US INC | $263.96 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $118.54 | 2019-2023 | Endosee, Mara Console, Summit Doppler |
| Therapeuticsmd, INC. | $96.61 | 2019-2021 | |
| Daiichi Sankyo INC. | $81.55 | 2021-2025 | Injectafer |
| Shield Therapeutics INC | $81.22 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $73.39 | 2021-2024 | Gardasil 9, Gardasil |
| Cumberland Pharmaceuticals, INC. | $61.38 | 2019-2025 | Kristalose |
| Mayne Pharma Commercial LLC | $59.68 | 2021 | |
| Pfizer INC. | $57.39 | 2022-2025 | |
| Mylan Pharmaceuticals INC. | $56.15 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.10 | 2020 | |
| Lumenis, INC | $52.42 | 2021 | |
| Sage Therapeutics, LLC | $50.29 | 2021-2024 | |
| Hologic Sales and Service, LLC | $48.03 | 2020-2023 | Thinprep 2000 Processor, Aptima |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36.00 | 2019-2020 | |
| Avion Pharmaceuticals | $32.24 | 2021 | |
| Amgen INC. | $30.72 | 2020-2022 | |
| Organon LLC | $25.95 | 2021 | |
| Roche Diagnostics Corporation | $23.24 | 2019 | |
| Millicent US INC | $23.21 | 2024 | Femring, Intrarosa |
| Sumitomo Pharma America, INC. | $18.86 | 2025 | Gemtesa |
| Evofem Biosciences, INC. | $18.83 | 2021 | |
| Amag Pharmaceuticals, INC. | $16.04 | 2019 | |
| Exeltis, USA INC. | $15.49 | 2024 | Slynd |
| Sanofi Pasteur INC. | $12.47 | 2019 | |
| Mckesson Patient Care Solutions INC. | $10.84 | 2019 | |
| Gen-Probe, INC. | $6.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.